Tracked vehiclesAnduril Enterprise 0.87% fill $173.4M / $20BCBP AST 46.50% fill $929.9M / $2.0BPalantir Maven 81.60% fill $637.6M / $781.3MShield AI USCG $61.4M drawn 12 ordersCounter-drone $2.1B drawn 25 C-UAS vehicles and awardsUSAspending compile · Oct 9 2026
AwardTape

AwardTape · Defense awards · Medical · Diagnostics and lab supplies · W81K0218P0246

W81K0218P0246: $0 purchase order to Revvity Health Sciences, Inc

Revvity Health Sciences, Inc holds a purchase order from Department of the Army with $0 obligated since Oct 2023 and $33K obligated over its life, against a ceiling of $33K. Latest action Apr 29, 2024.

Purchase of vasopressin (base) 1 oct 2018-30 sep 2019

PIIDW81K0218P0246
Typepurchase order
CompanyRevvity Health Sciences, Inc
AgencyDepartment of the Army
Contracting officeW40M MRCO PACIFIC
CategoryMedical · Diagnostics and lab supplies
PSC6550 IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS
NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING
Obligated since Oct 2023$0
Total obligated (lifetime)$33K
Ceiling (base and all options)$33K
Base dateSep 7, 2018
Latest actionApr 29, 2024
End dateSep 30, 2023
Actions since Oct 20231
PricingFirm fixed price
CompetitionNot competed under simplified acquisition
Place of performanceCT
SourceUSAspending.gov record
Reporting lagDoD 90 days
About this record

Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Place of performance shows the state only.

Terminal: alerts on new orders and modifications to this contract, and CSV export.

7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.

Start free trial